Dianthus Therapeutics, Inc. short interest in 2023
In 2023, Dianthus Therapeutics, Inc.'s disclosed short interest ran from 1.01% of shares outstanding on 13 Jan 2023 to 0.31% on 29 Dec 2023, a change of -0.70 percentage points. The year's high was 1.96% on 31 Mar 2023 and its low 0.13% on 15 Nov 2023, averaging 0.78% across 17 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 6.33 days on 28 Apr 2023. Full history: Dianthus Therapeutics, Inc..
Cite this page
By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2023 in figures
- Start of year
- 1.01% (13 Jan 2023)
- End of year
- 0.31% (29 Dec 2023)
- Change
- -0.70 pp
- High
- 1.96% (31 Mar 2023)
- Low
- 0.13% (15 Nov 2023)
- Average
- 0.78%
- Highest days to cover
- 6.33 (28 Apr 2023)
- SEC filings marked
- 6
Every report in 2023
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 13 Jan 2023 | 1.01% | 1.00 | |
| 31 Jan 2023 | 0.69% | 1.00 | |
| 31 Mar 2023 | 1.96% | 4.61 | results (8-K), 10-K filed |
| 14 Apr 2023 | 1.76% | 4.09 | |
| 28 Apr 2023 | 1.53% | 6.33 | |
| 15 May 2023 | 0.67% | 1.00 | 10-Q filed |
| 31 May 2023 | 0.82% | 1.23 | |
| 15 Jun 2023 | 0.88% | 1.25 | |
| 30 Jun 2023 | 0.93% | 1.42 | |
| 14 Jul 2023 | 0.65% | 1.80 | |
| 31 Jul 2023 | 0.47% | 1.00 | |
| 15 Aug 2023 | 0.63% | 1.45 | 10-Q filed |
| 31 Aug 2023 | 0.43% | 1.37 | |
| 15 Nov 2023 | 0.13% | 1.20 | 10-Q filed, results (8-K) |
| 30 Nov 2023 | 0.13% | 1.34 | |
| 15 Dec 2023 | 0.18% | 1.04 | |
| 29 Dec 2023 | 0.31% | 1.09 |
See also: Dianthus Therapeutics, Inc.'s full history · most shorted US stocks of 2023 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.